Narrowband UVB light therapy for moderate to severe plaque psoriasis
Part of Skin clinical trials.
This study tests whether narrowband ultraviolet B (UVB) light given three times a week for 12 weeks improves moderate-to-severe plaque psoriasis. It is an “open-label” pilot, meaning everyone gets the UVB treatment and researchers track how your skin responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with plaque-type psoriasis for at least 6 months
- Your psoriasis is in the moderate-to-severe range (based on skin area and severity scores used by the clinic)
- You can attend UVB phototherapy 3 times per week for 12 weeks and come to required visits
- You can sign informed consent and you’re generally healthy aside from psoriasis (as judged by the study doctor)
- You have no other psoriasis types (like pustular, erythrodermic, or guttate) and it’s not drug-induced psoriasis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.